Small biotechs dominate the pipeline for microbiome-targeted therapies; report

Research in the microbiome-targeted therapeutics has been in the news for some time, so the latest report from a leading data and analytics company is a timely look at some of the players.

With smaller biotech companies dominating the pipeline for microbiome-targeted therapeutics, large pharma firms, such as Johnson & Johnson (NYSE: JNJ), are eager to collaborate with biotech companies and academic labs to further the development of microbiome-targeted therapeutics in immunology, according to GlobalData.

The company’s report, titled Microbiome-Targeted Therapeutics in Immunology, focuses on the development of therapies targeting the skin microbiome for the treatment of acne, atopic dermatitis and psoriasis, and on treatments targeting the gut microbiome for the treatment of Crohn’s disease, ulcerative colitis and irritable bowel syndrome (IBS).